Nektar Therapeutics (NASDAQ:NKTR) SVP Ivan P. Gergel Sells 45,080 Shares

Nektar Therapeutics (NASDAQ:NKTR) SVP Ivan P. Gergel sold 45,080 shares of the company’s stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $21.08, for a total value of $950,286.40. Following the completion of the sale, the senior vice president now owns 51,961 shares of the company’s stock, valued at approximately $1,095,337.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Nektar Therapeutics (NASDAQ NKTR) traded up 1.73% during trading on Friday, reaching $18.26. The company had a trading volume of 1,240,270 shares. Nektar Therapeutics has a 52 week low of $11.41 and a 52 week high of $24.88. The company’s market capitalization is $2.84 billion. The stock’s 50-day moving average price is $20.60 and its 200-day moving average price is $18.28.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.04. The company had revenue of $34.60 million during the quarter, compared to analysts’ expectations of $33.64 million. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. Nektar Therapeutics’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.36) earnings per share. On average, equities analysts expect that Nektar Therapeutics will post ($1.02) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Nektar Therapeutics (NASDAQ:NKTR) SVP Ivan P. Gergel Sells 45,080 Shares” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/08/11/ivan-p-gergel-sells-45080-shares-of-nektar-therapeutics-nasdaqnktr-stock-updated-updated-updated.html.

Several large investors have recently bought and sold shares of NKTR. Flinton Capital Management LLC raised its stake in Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 448 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Nektar Therapeutics by 14.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 692 shares during the period. Meadow Creek Investment Management LLC boosted its position in Nektar Therapeutics by 11.1% in the first quarter. Meadow Creek Investment Management LLC now owns 6,160 shares of the biopharmaceutical company’s stock worth $145,000 after buying an additional 616 shares in the last quarter. LS Investment Advisors LLC boosted its position in Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 535 shares in the last quarter. Finally, Glen Harbor Capital Management LLC boosted its position in Nektar Therapeutics by 11.1% in the first quarter. Glen Harbor Capital Management LLC now owns 7,840 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 784 shares in the last quarter. Institutional investors and hedge funds own 94.09% of the company’s stock.

NKTR has been the subject of a number of analyst reports. Jefferies Group LLC reduced their price target on Nektar Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Wednesday, May 10th. Aegis restated a “buy” rating and issued a $27.00 price target on shares of Nektar Therapeutics in a research report on Wednesday, May 10th. Roth Capital set a $31.00 price target on Nektar Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 11th. BidaskClub upgraded Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Finally, William Blair reiterated an “outperform” rating on shares of Nektar Therapeutics in a research report on Tuesday, July 18th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. Nektar Therapeutics presently has a consensus rating of “Buy” and an average price target of $26.78.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

What are top analysts saying about Nektar Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nektar Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit